Refine
Year of publication
Document Type
- Preprint (633)
- Article (370)
- Contribution to a Periodical (3)
- Working Paper (2)
Has Fulltext
- yes (1008)
Is part of the Bibliography
- no (1008)
Keywords
- Heavy Ion Experiments (19)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- Heavy-ion collision (6)
- Collective Flow (4)
- Jets (4)
- LHC (4)
- Quark-Gluon Plasma (4)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- ALICE experiment (2)
- COVID-19 (2)
- Charm physics (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Germany (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- acute myeloid leukemia (2)
- childhood acute myeloid leukemia (2)
- relapse (2)
- salvage therapy (2)
- 3years (1)
- 900 GeV (1)
- ALICE (1)
- ALICE detector (1)
- ALK-rearranged NSCLC (1)
- Active middle ear implants (1)
- Acute kidney injury (1)
- Alcorrín (1)
- Animal model (1)
- Anti-nuclei (1)
- Auditory system (1)
- Autologous stem cell transplantation (1)
- Beauty production (1)
- Bike-Sharing (1)
- Bipolar disorder (1)
- Blood loss (1)
- Bone conduction devices (1)
- Bone tumor (1)
- Boosted Jets (1)
- Bronce Final (1)
- CTLA-4 (1)
- CVD biomarker (1)
- Car-Sharing (1)
- Centrality Class (1)
- Centrality Selection (1)
- Cleanliness level (1)
- Collective Flow, (1)
- Colloids (1)
- Colon capsule endoscopy (1)
- Complementation rate (1)
- Congenital ocular motor apraxia (1)
- Consensus statement (1)
- Couch tracking (1)
- DME (1)
- DNA methylation (1)
- Deutschland (1)
- Diagnostic markers (1)
- EBV (1)
- Early Iron Age (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elektromobilität (1)
- Elliptic flow (1)
- Endocrine cancer (1)
- Estrecho de Gibraltar (1)
- Extended donor criteria (1)
- Fibre/foam sandwich radiator (1)
- Flottenkonzepte (1)
- Forschung (1)
- Fortifica (1)
- General relativity (1)
- General relativity equations & solutions (1)
- Gimbaled tracking (1)
- Graft function (1)
- Graft survival (1)
- HES (1)
- HNO (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Health policy (1)
- Heavy Ion Experiment (1)
- Heavy Quark Production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- High-dose chemotherapy (1)
- Hydroxyethyl starch (1)
- ILUVIEN (1)
- IgG4-related disease (1)
- Incomplete colonoscopy (1)
- Indeterminate biliary stricture (1)
- Indigenous Peoples (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- Joubert syndrome (1)
- Krebsforschung (1)
- LTER (1)
- Ladeinfrastruktur (1)
- Late Bronze Age (1)
- Lehre (1)
- Lenalidomide (1)
- Lepton-Nucleon Scattering (experiments) (1)
- Liver transplantation (1)
- Long‐term ecosystem research (1)
- Low volume prep (1)
- MLC tracking (1)
- Marginal grafts (1)
- Minimum Bias (1)
- Mixed hearing loss (1)
- Mobil-Stationen (1)
- Molar tooth sign (1)
- Monte Carlo (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-stakeholder approach (1)
- Multi-wire proportional drift chamber (1)
- Multiple myeloma (1)
- Neural network (1)
- Neuroendocrine cancer (1)
- Next-generation sequencing (1)
- Nucleosynthesis in explosive environments (1)
- ORL (1)
- Organ motion (1)
- Organ rinse (1)
- Organ shortage (1)
- Otorhinolaryngology (1)
- PCR (1)
- PD-1 (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pedelecs (1)
- Phoenician Writing (1)
- Phoenicians (1)
- Phospho-soda (1)
- PillCamColon2 (1)
- Polyps (1)
- Primera Edad del Hierro (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Quark Deconfinement (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- Rabbit (1)
- Radiofrequency ablation (1)
- Rapidity Range (1)
- Rehabilitation (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Research (1)
- Research infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Retro-IDEAL (1)
- Robotic tracking (1)
- SARS-CoV-2 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- Second-line treatment (1)
- Single electrons (1)
- Site networks (1)
- Specialist training (1)
- Steroid (1)
- Strait of Gibraltar (1)
- Surgery (1)
- Systematic Uncertainty (1)
- TP53 mutation status (1)
- TR (1)
- Tacrolimus (1)
- Teaching (1)
- Technical data (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transient & explosive astronomical phenomena (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trauma (1)
- Trigger (1)
- Tumor therapy (1)
- Umweltbilanz (1)
- University hospitals (1)
- Universitätskliniken (1)
- VX-2 (1)
- Vector Boson Production (1)
- Volume therapy (1)
- Weiterbildung (1)
- Xenon-based gas mixture (1)
- adolescents’ health (1)
- advanced melanoma (1)
- allocation (1)
- bile duct stenosis (1)
- biliary stricture (1)
- biofilm (1)
- child (1)
- cholangiocarcinoma (1)
- complete response (1)
- dE/dx (1)
- dental implant (1)
- discontinuation (1)
- disease progression (1)
- ectosomes (1)
- electrolytic cleaning (1)
- endoscopic retrograde cholangiopancreatography (1)
- endoscopy (1)
- eosinophilic cholangitis (1)
- escritura fenicia (1)
- exosomes (1)
- extracellular vesicles (1)
- fenicios (1)
- fortificación, (1)
- fourth (1)
- graft (1)
- guidelines (1)
- heavy ion experiments (1)
- immune checkpoint blockade (1)
- immunohistochemistry (1)
- indígenas (1)
- infection (1)
- kidney (1)
- kidney transplantation (1)
- liver metastasis (1)
- liver transplantation (1)
- loss (1)
- microdosing (1)
- microparticles (1)
- microsatellite instability (1)
- microvesicles (1)
- minimal information requirements (1)
- multidrug resistance (1)
- multisite cooperation (1)
- neutralizing antibodies (1)
- nocardia (1)
- nocardiosis (1)
- paediatric nephrology (1)
- pediatric (1)
- pediatric patients (1)
- periimplantitis (1)
- perio-prosthetic joint infection (1)
- personalized oncology (1)
- pp collisions (1)
- primary sclerosing cholangitis (1)
- pulmonary nocardiosis (1)
- quark gluon plasma (1)
- re-transplantation (1)
- recurrent cholangitis (1)
- repeated (1)
- reproducibility (1)
- research consortium (1)
- rigor (1)
- risk factor progression (1)
- risk factors (1)
- second-line immunotherapy (1)
- sequential ALK-inhibitor therapy (1)
- short-course antibiotic therapy (1)
- spike protein (1)
- standardization (1)
- survival (1)
- targeted therapy (1)
- third (1)
- transfer (1)
- transition (1)
- translational cancer research (1)
- treatment resistance (1)
- uveal melanoma (1)
- variants of concern (1)
Institute
- Physik (957)
- Frankfurt Institute for Advanced Studies (FIAS) (886)
- Informatik (855)
- Medizin (36)
- Informatik und Mathematik (3)
- Präsidium (3)
- Geographie (2)
- Geowissenschaften (2)
- Hochschulrechenzentrum (2)
- Biowissenschaften (1)
Background: Trauma may be associated with significant to life-threatening blood loss, which in turn may increase the risk of complications and death, particularly in the absence of adequate treatment. Hydroxyethyl starch (HES) solutions are used for volume therapy to treat hypovolemia due to acute blood loss to maintain or re-establish hemodynamic stability with the ultimate goal to avoid organ hypoperfusion and cardiovascular collapse. The current study compares a 6% HES 130 solution (Volulyte 6%) versus an electrolyte solution (Ionolyte) for volume replacement therapy in adult patients with traumatic injuries, as requested by the European Medicines Agency to gain more insights into the safety and efficacy of HES in the setting of trauma care.
Methods: TETHYS is a pragmatic, prospective, randomized, controlled, double-blind, multicenter, multinational trial performed in two parallel groups. Eligible consenting adults ≥ 18 years, with an estimated blood loss of ≥ 500 ml, and in whom initial surgery is deemed necessary within 24 h after blunt or penetrating trauma, will be randomized to receive intravenous treatment at an individualized dose with either a 6% HES 130, or an electrolyte solution, for a maximum of 24 h or until reaching the maximum daily dose of 30 ml/kg body weight, whatever occurs first. Sample size is estimated as 175 patients per group, 350 patients total (α = 0.025 one-tailed, power 1–β = 0.8). Composite primary endpoint evaluated in an exploratory manner will be 90-day mortality and 90-day renal failure, defined as AKIN stage ≥ 2, RIFLE injury/failure stage, or use of renal replacement therapy (RRT) during the first 3 months. Secondary efficacy and safety endpoints are fluid administration and balance, changes in vital signs and hemodynamic status, changes in laboratory parameters including renal function, coagulation, and inflammation biomarkers, incidence of adverse events during treatment period, hospital, and intensive care unit (ICU) length of stay, fitness for ICU or hospital discharge, and duration of mechanical ventilation and/or RRT.
Discussion: This pragmatic study will increase the evidence on safety and efficacy of 6% HES 130 for treatment of hypovolemia secondary to acute blood loss in trauma patients.
Trial registration:Registered in EudraCT, No.: 2016-002176-27 (21 April 2017) and ClinicalTrials.gov, ID: NCT03338218 (09 November 2017).
Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1–21 of 28 day cycles) followed by 10–15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (p = 0.57). Progression-free survival (PFS; HR = 0.83, p = 0.18) and overall survival (OS; HR = 0.70, p = 0.15) did not differ significantly with LEN vs. BTZ MT. Patients with <nCR after first ASCT were assigned tandem ASCT in both trials. In patients with <nCR and tandem ASCT (LEN: n = 54 vs. BTZ: n = 84), LEN MT significantly improved PFS (HR = 0.61, p = 0.04) but not OS (HR = 0.46, p = 0.09). In conclusion, the significant PFS benefit after eliminating the impact of different tandem ASCT rates supports the current standard of LEN MT after ASCT.
The inclusive charged particle transverse momentum distribution is measured in proton–proton collisions at s=900 GeV at the LHC using the ALICE detector. The measurement is performed in the central pseudorapidity region (|η|<0.8) over the transverse momentum range 0.15<pT<10 GeV/c. The correlation between transverse momentum and particle multiplicity is also studied. Results are presented for inelastic (INEL) and non-single-diffractive (NSD) events. The average transverse momentum for |η|<0.8 is 〈pT〉INEL=0.483±0.001 (stat.)±0.007 (syst.) GeV/c and 〈pT〉NSD=0.489±0.001 (stat.)±0.007 (syst.) GeV/c, respectively. The data exhibit a slightly larger 〈pT〉 than measurements in wider pseudorapidity intervals. The results are compared to simulations with the Monte Carlo event generators PYTHIA and PHOJET.
Background: Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone compared with placebo/dexamethasone in relapsed MM (RMM) patients. These results have led to the approval of lenalidomide for RMM patients and lenalidomide/dexamethasone has since become a widely accepted second-line treatment. Furthermore, in RMM patients consolidation with high-dose chemotherapy plus autologous stem cell transplantation has been shown to significantly increase progression free survival (PFS) as compared to cyclophosphamide in a phase III trial. The randomized prospective ReLApsE trial is designed to evaluate PFS after lenalidomide/dexamethasone induction, high-dose chemotherapy consolidation plus autologous stem cell transplantation and lenalidomide maintenance compared with the well-established lenalidomide/dexamethasone regimen in RMM patients.
Methods/Design: ReLApsE is a randomized, open, multicenter phase III trial in a planned study population of 282 RMM patients. All patients receive three lenalidomide/dexamethasone cycles and - in absence of available stem cells from earlier harvesting - undergo peripheral blood stem cell mobilization and harvesting. Subsequently, patients in arm A continue on consecutive lenalidomide/dexamethasone cycles, patients in arm B undergo high dose chemotherapy plus autologous stem cell transplantation followed by lenalidomide maintenance until discontinuation criteria are met. Therapeutic response is evaluated after the 3rd (arm A + B) and the 5th lenalidomide/dexamethasone cycle (arm A) or 2 months after autologous stem cell transplantation (arm B) and every 3 months thereafter (arm A + B). After finishing the study treatment, patients are followed up for survival and subsequent myeloma therapies. The expected trial duration is 6.25 years from first patient in to last patient out. The primary endpoint is PFS, secondary endpoints include overall survival (OS), RR, time to best response and the influence of early versus late salvage high dose chemotherapy plus autologous stem cell transplantation on OS.
Discussion: This phase III trial is designed to evaluate whether high dose chemotherapy plus autologous stem cell transplantation and lenalidomide maintenance after lenalidomide/dexamethasone induction improves PFS compared with the well-established continued lenalidomide/dexamethasone regimen in RMM patients. Trial registration: ISRCTN16345835 (date of registration 2010-08-24).
High attrition rates of novel anti-cancer drugs highlight the need for improved models to predict toxicity. Although polo-like kinase 1 (Plk1) inhibitors are attractive candidates for drug development, the role of Plk1 in primary cells remains widely unexplored. Therefore, we evaluated the utility of an RNA interference-based model to assess responses to an inducible knockdown (iKD) of Plk1 in adult mice. Here we show that Plk1 silencing can be achieved in several organs, although adverse events are rare. We compared responses in Plk1-iKD mice with those in primary cells kept under controlled culture conditions. In contrast to the addiction of many cancer cell lines to the non-oncogene Plk1, the primary cells' proliferation, spindle assembly and apoptosis exhibit only a low dependency on Plk1. Responses to Plk1-depletion, both in cultured primary cells and in our iKD-mouse model, correspond well and thus provide the basis for using validated iKD mice in predicting responses to therapeutic interventions.
The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field in 2014. We now update these “MISEV2014” guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV-associated functional activities. Finally, a checklist is provided with summaries of key points.
Simple Summary: The introduction of BRAF/MEK-directed targeted therapy (TT) has significantly improved the management of patients with advanced BRAF-V600-mutant melanoma. Although resistance occurs, there is a subgroup of patients showing a complete response (CR) to TT and who maintain durable disease control. For these patients with durable CR, it is not clear whether it is safe to cease therapy. In this retrospective, multicenter study we have analyzed 37 patients who received TT and achieved a CR upon treatment. We identified 15 patients with a durable CR to TT. Overall, patients who discontinued TT (n = 26) were at higher risk of tumor progression compared to patients receiving ongoing TT. Sustained CR was however not restricted to patients with ongoing TT (n = 11) but was also found in patients who ceased TT (n = 4). Finally, our analysis indicated which patients with an initial CR might be most likely to maintain durable CR upon discontinuation of TT.
Abstract: The advent of BRAF/MEK inhibitors (BRAFi/MEKi) has significantly improved progression-free (PFS) and overall survival (OS) for patients with advanced BRAF-V600-mutant melanoma. Long-term survivors have been identified particularly among patients with a complete response (CR) to BRAF/MEK-directed targeted therapy (TT). However, it remains unclear which patients who achieved a CR maintain a durable response and whether treatment cessation might be a safe option in these patients. Therefore, this study investigated the impact of treatment cessation on the clinical course of patients with a CR upon BRAF/MEK-directed-TT. We retrospectively selected patients with BRAF-V600-mutant advanced non-resectable melanoma who had been treated with BRAFi ± MEKi therapy and achieved a CR upon treatment out of the multicentric skin cancer registry ADOReg. Data on baseline patient characteristics, duration of TT, treatment cessation, tumor progression (TP) and response to second-line treatments were collected and analyzed. Of 461 patients who received BRAF/MEK-directed TT 37 achieved a CR. TP after initial CR was observed in 22 patients (60%) mainly affecting patients who discontinued TT (n = 22/26), whereas all patients with ongoing TT (n = 11) maintained their CR. Accordingly, patients who discontinued TT had a higher risk of TP compared to patients with ongoing treatment (p < 0.001). However, our data also show that patients who received TT for more than 16 months and who discontinued TT for other reasons than TP or toxicity did not have a shorter PFS compared to patients with ongoing treatment. Response rates to second-line treatment being initiated in 21 patients, varied between 27% for immune-checkpoint inhibitors (ICI) and 60% for BRAFi/MEKi rechallenge. In summary, we identified a considerable number of patients who achieved a CR upon BRAF/MEK-directed TT in this contemporary real-world cohort of patients with BRAF-V600-mutant melanoma. Sustained PFS was not restricted to ongoing TT but was also found in patients who discontinued TT.
Introduction: The Retro-IDEAL (ILUVIEN Implant for chronic DiabEtic MAcuLar edema) study is a retrospective study designed to assess real-world outcomes achieved with the ILUVIEN® (0.19 mg fluocinolone acetonide (FAc)) in patients with chronic diabetic macular edema (DME) in clinical practices in Germany.
Methods: This study was conducted across 16 sites in Germany and involved 81 eyes (63 patients) with persistent or recurrent DME and a prior suboptimal response to a first-line intravitreal therapy (primarily anti-VEGF intravitreal therapies).
Results: Patients were followed-up for 30.8 ± 11.3 months (mean ± standard deviation) and had a mean age of 68.0 ± 10.4 years. Best-recorded visual acuity (BRVA) improved by +5.5 letters at month 9 (P ⩽ 0.005, n=56; from a baseline of 49 letters) and this was maintained through to month 30 (P ⩽ 0.05, n = 42). There was a concurrent improvement in central macular thickness with a reduction from 502 µm at baseline to 338 µm at year 1 (P ⩽ 0.0001, n = 43). This effect was sustained to year 3 (i.e. 318 µm; P ⩽ 0.0001, n = 29). Mean intraocular pressure (IOP) remained constant between baseline and year 3 with a peak change of 1.9 mm Hg occurring at year 1. Elevated IOP was observed in a similar percentage of patients prior to (22.2% of cases) and following (27.2%) treatment with the FAc implant. In the majority of cases, these elevations were managed effectively with IOP medications.
Conclusions: Despite substantial amounts of prior intravitreal treatments – primarily with anti–vascular endothelial growth factor (VEGF) drugs – this real-world study showed that sustained structural and functional improvements can last for up to 3 years with a single FAc implant.
Nosological delineation of congenital ocular motor apraxia type Cogan : an observational study
(2016)
Background: The nosological assignment of congenital ocular motor apraxia type Cogan (COMA) is still controversial. While regarded as a distinct entity by some authorities including the Online Mendelian Inheritance in Man catalog of genetic disorders, others consider COMA merely a clinical symptom.
Methods: We performed a retrospective multicenter data collection study with re-evaluation of clinical and neuroimaging data of 21 previously unreported patients (8 female, 13 male, ages ranging from 2 to 24 years) diagnosed as having COMA.
Results: Ocular motor apraxia (OMA) was recognized during the first year of life and confined to horizontal pursuit in all patients. OMA attenuated over the years in most cases, regressed completely in two siblings, and persisted unimproved in one individual. Accompanying clinical features included early onset ataxia in most patients and cognitive impairment with learning disability (n = 6) or intellectual disability (n = 4). Re-evaluation of MRI data sets revealed a hitherto unrecognized molar tooth sign diagnostic for Joubert syndrome in 11 patients, neuroimaging features of Poretti-Boltshauser syndrome in one case and cerebral malformation suspicious of a tubulinopathy in another subject. In the remainder, MRI showed vermian hypo-/dysplasia in 4 and no abnormalities in another 4 patients. There was a strong trend to more severe cognitive impairment in patients with Joubert syndrome compared to those with inconclusive MRI, but otherwise no significant difference in clinical phenotypes between these two groups.
Conclusions: Systematical renewed analysis of neuroimaging data resulted in a diagnostic reappraisal in the majority of patients with early-onset OMA in the cohort reported here. This finding poses a further challenge to the notion of COMA constituting a separate entity and underlines the need for an expert assessment of neuroimaging in children with COMA, especially if they show cognitive impairment.
Carma-1 is required for B cell receptor-/CD40- and T cell receptor-/CD28-induced B- and T-cell activation via JNK and NF-betaB. In B cells, Carma-1 becomes phosphorylated by PKCbeta, leading to its oligomerization. Subsequent Bcl10 binding induces IKKbeta-activation and, thereby, canonical NF-KB signalling. Despite these findings it is still unknown how exactly Carma-1 is connected to the plasma membrane and to the IKK-complex. Therefore, we purified Carma-1 complexes from mouse CH12 B cells using anti-Carma-1 affinity columns. Mass spectrometric analyses of the column eluates demonstrated the presence of Carma-1 as well as three previously uncharacterized adaptor proteins in B cells, one of which was the Trk-fused gene (Tfg), an adaptor protein containing PB1 and coiledcoil domains. Whereas Tfg was originally identified as fusion partner of oncogenic Trk tyrosine kinase mutants, the normal cellular homologue of Tfg has so far not been described in B cells. However, Tfg has been shown in other systems to interact with IKKgamma and to enhance TNFinduced NF-KB activation. Tfg and Carma-1 co-localized at the plasma membrane and perinuclear structures in B cells. We further corroborated the interactions of Tfg, IKKgamma and Carma-1 by Blue Native gel electrophoresis, where Carma-1 and Tfg formed a 0.7–1 MDa complex. Ectopic expression of Tfg increased the molecular mass of IKKgamma complexes, fused IKKgamma, Bcl10 and Carma-1 complexes to a ~2 MDa complex, and increased basal and CD40-induced canonical activity of NF-KB and IKKbeta. In contrast, shRNA-mediated silencing of Tfg decreased CD40-induced IKKbeta activity. Very interestingly, in primary B cells, highest expression of Tfg was detected in marginal zone and B1 B cells, and Carma-1 and Tfg formed complexes in these B cells. Since Carma-1 is required for marginal zone B cell and B1 B cell development, we suggest that a functional interaction between Carma-1 and Tfg contributes to development and maintenance of these cells by means of canonical NF-KB signals.